Cardiol Therapeutics Registered (A) WKN: A2PA9E ISIN: CA14161Y2006 Forum: Aktien Thema: Hauptdiskussion

Cardiol Therapeutics looks ahead to busy 2022 as it advances new treatment options for cardiovascular disease https://www.proactiveinvestors.com/companies/news/977760/cardiol-therapeutics-looks-ahead-to-busy-2022-as-it-advances-new-treatment-options-for-cardiovascular-disease-977760.html Oakville, Ontario – 24. März 2022 – Cardiol Therapeutics Inc. https://www.irw-press.com/de/news/cardiol-therapeutics-berichtet-aus-dem-aktuellen-betrieb-zum-ende-des-geschaeftsjahres-2021_64904.html?isin=CA14161Y2006

Leider alles wieder weg

Schöner Start

ruhe bewahren auch wenns schwer fällt. wird alles gut

Super.nur noch bergab

https://finance.yahoo.com/news/cardiol-therapeutics-receives-clearance-fda-122700335.html

The Company expects the LANCER trial to achieve over 50% patient recruitment by the end of the first half of 2022 and to complete full patient enrollment during the second half of 2022. In addition to expanding site recruitment, the Company, in consultation with the LANCER Steering Committee, has amended the trial protocol in response to the evolving understanding of COVID-19 and the current standard of care. These updates are expected to remove key barriers to participation in LANCER as well as expand the eligible patient pool and include the following: (i) vaccinated people may be enrolled; (ii) use of therapies approved for treatment of COVID-19 under an emergency use authorization label is permitted; and (iii) a prior history of smoking or obesity, both CVD risk factors prevalent in younger patients, will allow entry into the trial. Furthermore, the Company expects Brazil to be a key contributor to patient enrollment given the country is approaching its winter season, the pace of vaccine booster administration is slow, and the pre-winter case rate is currently averaging approximately 100,000 per day.

Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial

Warum der starke Anstieg?

Geht's hier eigentlich nur runter

Oueeoueeouee .. sorry Leute musste das loswerden 😉

.

Raymond James Kursziel 5C$

https://www.tipranks.com/news/blurbs/cardiol-therapeutics-crdl-receives-a-buy-from-raymond-james?utm_source=stck.pro&utm_medium=referral

https://www.fool.ca/2022/01/31/1-top-healthcare-stock-to-buy-low-today/

https://ceo.ca/@newsfile/cardiol-therapeutics-appoints-thought-leaders-in-cardiovascular